RxDoctor Payments Data

Michael Press, DO

Nephrology · Lawrenceville, GANPI 1497783765

Payments from drug & device makers

$3,528in general payments, 2019–2025

Across 133 payments — averaging $26.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$523
  • AstraZeneca$349
  • Nxstage Medical, Inc.$306
  • Travere Therapeutics, Inc.$267
  • Otsuka America Pharmaceutical, Inc.$234
  • Mallinckrodt Hospital Products Inc.$230
  • plus $2K from 20 others

What the payments were for

  • Speaking & faculty fees$2507%
  • Food & beverage$3,23592%
  • Education$431%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,528 in reported general payments places this provider in the 65th percentile of 388 nephrology providers in Georgia.

See all nephrology providers in Georgia

Medicare billing

Part B allowed, 2024
$152,623
Medicare patients
304
Services billed
1,134

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide14$40,353
FarxigaDapagliflozin Propanediol33$38,335
VeltassaPatiromer Calcium Sorbitex31$32,799
LokelmaSodium Zirconium Cyclosilicate13$7,904
Calcitriol220$2,780
Sevelamer Carbonate16$2,694
Nifedipine ErNifedipine47$2,361
Doxazosin Mesylate58$1,448
Valsartan35$1,365
Allopurinol166$1,091
Losartan Potassium107$828
Rosuvastatin Calcium54$757
Metoprolol Succinate47$756
Spironolactone47$689
Hydralazine Hcl74$587

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$349$46,23846 claims
Fresenius USA Marketing, Inc.Velphoro$193$40,35314 claims
ANI Pharmaceuticals, Inc.Valsartan$67$1,36535 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 nephrology providers in Georgia.

Other nephrology in Lawrenceville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →